Cargando…
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
OBJECTIVE: We evaluated the metabolic effects and tolerability of GFT505, a novel dual peroxisome proliferator–activated receptor α/δ agonist, in abdominally obese patients with either combined dyslipidemia or prediabetes. RESEARCH DESIGN AND METHODS: The S1 study was conducted in 94 patients with c...
Autores principales: | Cariou, Bertrand, Zaïr, Yassine, Staels, Bart, Bruckert, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161281/ https://www.ncbi.nlm.nih.gov/pubmed/21816979 http://dx.doi.org/10.2337/dc11-0093 |
Ejemplares similares
-
Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
por: Cariou, Bertrand, et al.
Publicado: (2013) -
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model
por: Liu, Linfu, et al.
Publicado: (2020) -
PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011) -
Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015) -
Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
por: Prawitt, Janne, et al.
Publicado: (2011)